KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $12.1 million.

  • Alnylam Pharmaceuticals' Capital Expenditures rose 18964.69% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year increase of 989.58%. This contributed to the annual value of $34.3 million for FY2024, which is 4490.2% down from last year.
  • Alnylam Pharmaceuticals' Capital Expenditures amounted to $12.1 million in Q3 2025, which was up 18964.69% from $14.3 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Capital Expenditures registered a high of $26.1 million during Q3 2021, and its lowest value of $4.2 million during Q3 2024.
  • For the 5-year period, Alnylam Pharmaceuticals' Capital Expenditures averaged around $14.8 million, with its median value being $15.3 million (2023).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Capital Expenditures tumbled by 7547.39% in 2024, and later surged by 18964.69% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Capital Expenditures (Quarter) stood at $21.9 million in 2021, then fell by 1.15% to $21.6 million in 2022, then dropped by 29.24% to $15.3 million in 2023, then crashed by 40.6% to $9.1 million in 2024, then skyrocketed by 33.52% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q3 2025, $14.3 million for Q2 2025, and $9.0 million during Q1 2025.